Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month High – Time to Buy?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a new 52-week high on Thursday . The stock traded as high as $14.48 and last traded at $14.4650, with a volume of 195389 shares changing hands. The stock had previously closed at $14.46.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Jefferies Financial Group restated a “hold” rating and issued a $14.50 price objective (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Leerink Partners downgraded shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $17.00 to $14.50 in a research note on Monday, December 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Friday, March 27th. Zacks Research downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 26th. Finally, Guggenheim downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $15.39.

Amicus Therapeutics Price Performance

The firm has a market capitalization of $4.54 billion, a price-to-earnings ratio of -180.81 and a beta of 0.48. The company’s 50 day moving average is $14.40 and its 200-day moving average is $12.43. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. During the same quarter in the prior year, the firm earned $0.09 EPS. The company’s revenue was up 23.7% on a year-over-year basis. Equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.43 earnings per share for the current year.

Insider Activity

In other news, CEO Bradley L. Campbell sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total transaction of $322,875.00. Following the completion of the sale, the chief executive officer owned 998,680 shares in the company, valued at $14,331,058. The trade was a 2.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. boosted its holdings in shares of Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 3,677 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 2,651.5% during the fourth quarter. Farther Finance Advisors LLC now owns 1,871 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,803 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Amicus Therapeutics by 167.1% during the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,243 shares during the period. Finally, Strs Ohio bought a new stake in shares of Amicus Therapeutics during the first quarter worth approximately $30,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.